Kape Biology announces that two major R&D projects have been delayed by one year, with a total investment of nearly 300 million yuan.

(March 18, 2026, Shantou) Guangdong Kaipu Biotechnology Co., Ltd. (Stock code: 300639, referred to as “Kaipu Biotech”) announced today that the company’s board of directors has approved a one-year extension for the expected date of readiness for the HPV drug development project and the nucleic acid molecular diagnostic product development project. Both core R&D projects, with a total investment exceeding 500 million yuan, were originally scheduled to be completed by March 2026, now adjusted to March 2027.

The announcement shows that the two fundraising projects delayed this time were both funded by the company’s private placement completed in 2020. At that time, the company issued 22.9458 million shares to eight specific investors at 45.76 yuan per share, raising a total of 1.05 billion yuan, with a net amount of 1.027 billion yuan. As of December 31, 2025, the cumulative investment in the two projects was as follows:

It is understood that the delay in these projects is mainly due to extended R&D and clinical trial cycles during the national emergency public health response, as well as the company’s adjustments to product development strategies based on market demand. Kaipu Biotech emphasizes that this extension will not change the project content or total investment amount, nor will it alter or covertly change the use of raised funds.

The company’s board of directors, independent directors, audit committee, and sponsor CITIC Securities have all expressed their approval of this extension. All parties agree that the delay is a cautious decision based on actual circumstances, aligns with the company’s development needs, and will not harm shareholders’ interests.

Kaipu Biotech states that it will strictly comply with relevant laws and regulations, strengthen supervision over the use of raised funds, and ensure the funds are used legally and effectively. Market analysts point out that as a leading enterprise in the domestic molecular diagnostics field, although the project delay may temporarily impact market expectations, in the long term it is beneficial for ensuring R&D quality and enhancing product competitiveness.

Click to view the original announcement >>

Disclaimer: The market carries risks; investment should be cautious. This article is automatically published by an AI large model based on third-party databases and does not represent Sina Finance’s views. Any information appearing in this article is for reference only and does not constitute personal investment advice. Please refer to the actual announcement for any discrepancies. If you have questions, contact biz@staff.sina.com.cn.